search
Back to results

Efficacy of Dexmedetomidine Versus Clonidine to Control Delirium in Patients Undergoing CABG

Primary Purpose

Delirium on Emergence

Status
Completed
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Dexmedetomidine
Clonidine
Sponsored by
Ain Shams University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Delirium on Emergence focused on measuring dexmedetomidine, clonidine, postoperative, CABG

Eligibility Criteria

60 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

60-70 yrs age ASA II, III Scheduled for CABG -

Exclusion Criteria:

History of mental illness Delirium or dementia patient refusal to participate Emergency procedures Any contraindications to study drugs

-

Sites / Locations

  • Ain Shams university

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

dexmedetomidine group

clonidine group

Arm Description

Upon arrival to ICU, in the dexmedetomidine group, patients will receive an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4 +4 Combative ,+3 Very agitated ,+2 Agitated,+1 Restless, 0 Alert and calm, -1 Drowsy , -2 Light sedation, -3 Moderate sedation, -4 Deep sedation, -5 Unarrousable Taking into consideration if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h. Once the patient will be extubated, wean the infusion by 0.1μg/kg/h till reaching 0.2μg/kg/h. Slow the weaning rate if evidence of withdrawal reactions as agitation or hypertension occur.

In clonidine group, the patients will receive 0.5μg/kg then 0.1-0.2 μg/kg/h if Richmond assessment sedation score from +1 to +4 Five ampoules of clonidine(750 μg) will be drawn up and diluted in 45ml of normal saline.

Outcomes

Primary Outcome Measures

the incidence of delirium
disturbed level of consciousness that develops over a period of hours or days and fluctuates over time.

Secondary Outcome Measures

length of ICU stay
time to stay in ICU discharge to the ward

Full Information

First Posted
March 20, 2018
Last Updated
July 10, 2019
Sponsor
Ain Shams University
search

1. Study Identification

Unique Protocol Identification Number
NCT03477994
Brief Title
Efficacy of Dexmedetomidine Versus Clonidine to Control Delirium in Patients Undergoing CABG
Official Title
Efficacy of Dexmedetomidine Versus Clonidine to Control Delirium in Patients Undergoing Coronary Artery Bypass Grafting
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
December 1, 2018 (Actual)
Primary Completion Date
February 28, 2019 (Actual)
Study Completion Date
February 28, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ain Shams University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This prospective, randomised, double blinded, controlled clinical trial will be conducted in 147 patients between 60 yr and 70 yr , ASA physical status II and III, undergoing CABG. Patients will be randomly allocated to either dexmedetomidine or clonidine (control) groups .Upon arrival to ICU, in the dexmedetomidine group, patients will receive an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4 Taking into consideration if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h. Once the patient will be extubated, wean the infusion by 0.1μg/kg/h till reaching 0.2μg/kg/h. Slow the weaning rate if evidence of withdrawal reactions as agitation or hypertension occur. In clonidine group, the patients will receive 0.5μg/kg then 0.1-0.2 μg/kg/h.Primary end point of the study is the incidence of delirium.The secondary endpoints will be the the duration of extubation, the length of ICU stay, need for inotropic support or vasopressors, hospital stay , mean arterial blood pressure and heart rate , hospital mortality rate , all additional sedatives including overall doses of morphine and haloperidol the incidence of adverse events as bradycardia
Detailed Description
After Ethics committee approval, and a written informed consent will be taken from every patient, . Patients with a history of mental illness, severe dementia, delirium or undergoing emergency procedures will be excluded. Anesthesia management will be standardized to minimize any effect of anesthetic type on neurological outcomes. Premedication with midazolam will be limited to a maximum of 0.05 mg/kg. Anesthesia will be induced with 12 μg/kg fentanyl, 5-7mg/kg thiopental sodium, and 0.15 mg/kg pancuronium and maintained with 1% to 2.0% isoflurane. The heart rate and blood pressure will be maintained within 20% of the baseline values. Anticoagulation will be achieved with heparin to maintain an activated clotting time above 480 s.The CPB circuit will be primed with 1.8 l lactated Ringer's solution and 50 ml of 20% mannitol. Management of CPB will include systemic temperature drift to 32 C, targeted mean perfusion pressure between 60 and 80 mmHg, and pump flow rates of 2.2 l/min/m2 . Myocardial protection will be achieved with antegrade cold blood cardioplegia. A 32-μ m filter (Avecor Affinity, USA)will be used in the arterial perfusion line. Before separation from CPB, patients will be rewarmed to 36 to 37C. After separation from CPB, heparin will be neutralized with protamine sulfate, 1 mg/100 U heparin, to reach an activated clotting time within 10% of baseline.All patients will be transferred to ICU after surgery. Patients will be randomly allocated to either dexmedetomidine or clonidine (control) groups according to a computer-generated randomization code, with allocation ratio 1:1 .Opaque sealed envelopes will be done according to the randomization schedule and opened by a physician not involved in the study . Upon arrival to ICU, in the dexmedetomidine group, patients will receive an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4 +4 Combative ,+3 Very agitated ,+2 Agitated,+1 Restless, 0 Alert and calm, -1 Drowsy , -2 Light sedation, -3 Moderate sedation, -4 Deep sedation, -5 Unarrousable A four millilitres vial of dexmedetomidine ( 100 micrograms per ml)will be drawn up and diluted in 46 ml of normal saline.The infusion of dexmedetomidine will be continued for a maximum period of 24 h. Taking into consideration if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h.Dexmedetomidine infusion will not be discontinued before extubation. Once the patient will be extubated, wean the infusion by 0.1μg/kg/h till reaching 0.2μg/kg/h. Slow the weaning rate if evidence of withdrawal reactions as agitation or hypertension occur. In clonidine group, the patients will receive 0.5μg/kg then 0.1-0.2 μg/kg/h. Five ampoules of clonidine(750 μg) was drawn up and diluted in 45ml of normal saline. Opioids were titrated to reach pain score 3 out of 10. Pain will be assessed using a standard 10-cm visual analog scale (0, no pain; 10, worst and unbearable pain). Patients received 2 mg morphine as rescue analgesic. Primary end point of the study is the incidence of delirium, which is defined as a disturbed level of consciousness that develops over a period of hours or days and fluctuates over time. Delirium will be assessed preoperatively (baseline)and postoperatively, in ICU every 2 hours using the confusion assessment method (CAM) for ICU.(7) When patients are discharged from ICU to the ward, delirium will be assessed using CAM every 8 hours for the next 5 days. The CAM-ICU is used for both ventilated and extubated patients. It included a fourstep algorithm : (1) an acute onset of changes or fluctuations in the course of mental status, (2)inattention, (3) disorganized thinking, and (4) an altered level of consciousness. Patients are delirious if both (1) and (2) were found inanition to either feature (3)or (4). Patients are stated either CAM positive (delirium present) or CAM negative (delirium absent). Incidence of delirium was confirmed by the psychiatry consultant. The onset and duration of delirium will be also recorded. The CAM-ICU and CAM testers were involved in the study . IV haloperidol(2.5-5 mg PRN), will be used as a first-line treatment in delirious patients, a regular dose 1 mg ads until symptoms resolve. The secondary endpoints will be the the duration of extubation, the length of ICU stay, need for inotropic support or vasopressors, hospital stay , mean arterial blood pressure and heart rate , hospital mortality rate , all additional sedatives including overall doses of morphine and haloperidol, finally the incidence of adverse events as bradycardia, heart block , the need for pacemaker , nausea and vomiting will be recorded as well.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Delirium on Emergence
Keywords
dexmedetomidine, clonidine, postoperative, CABG

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
147 (Actual)

8. Arms, Groups, and Interventions

Arm Title
dexmedetomidine group
Arm Type
Active Comparator
Arm Description
Upon arrival to ICU, in the dexmedetomidine group, patients will receive an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4 +4 Combative ,+3 Very agitated ,+2 Agitated,+1 Restless, 0 Alert and calm, -1 Drowsy , -2 Light sedation, -3 Moderate sedation, -4 Deep sedation, -5 Unarrousable Taking into consideration if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h. Once the patient will be extubated, wean the infusion by 0.1μg/kg/h till reaching 0.2μg/kg/h. Slow the weaning rate if evidence of withdrawal reactions as agitation or hypertension occur.
Arm Title
clonidine group
Arm Type
Sham Comparator
Arm Description
In clonidine group, the patients will receive 0.5μg/kg then 0.1-0.2 μg/kg/h if Richmond assessment sedation score from +1 to +4 Five ampoules of clonidine(750 μg) will be drawn up and diluted in 45ml of normal saline.
Intervention Type
Drug
Intervention Name(s)
Dexmedetomidine
Other Intervention Name(s)
demedetomidine hydrochloride
Intervention Description
an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4 ,if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h.
Intervention Type
Drug
Intervention Name(s)
Clonidine
Other Intervention Name(s)
clonidine hydrochloride
Intervention Description
an infusion of 0.5μg/kg then 0.1-0.2 μg/kg/h if Richmond assessment sedation score from +1 to +4.
Primary Outcome Measure Information:
Title
the incidence of delirium
Description
disturbed level of consciousness that develops over a period of hours or days and fluctuates over time.
Time Frame
every 4 hours in first day in ICU then every 8h for the next day, after discharge from ICU to the ward it will be checked every 8h for 5 days
Secondary Outcome Measure Information:
Title
length of ICU stay
Description
time to stay in ICU discharge to the ward
Time Frame
2 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 60-70 yrs age ASA II, III Scheduled for CABG - Exclusion Criteria: History of mental illness Delirium or dementia patient refusal to participate Emergency procedures Any contraindications to study drugs -
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ayman Shoeb, professor
Organizational Affiliation
Ain Shams University
Official's Role
Study Chair
Facility Information:
Facility Name
Ain Shams university
City
Cairo
ZIP/Postal Code
11566
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
IPD including protocol will be shared
IPD Sharing Time Frame
about one year
IPD Sharing Access Criteria
prevention of delirium post cardiac surgery

Learn more about this trial

Efficacy of Dexmedetomidine Versus Clonidine to Control Delirium in Patients Undergoing CABG

We'll reach out to this number within 24 hrs